Kartos Therapeutics

Biotech

kartosthera.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
36
2 granted · 34 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
296742Bio, LLC——
2968ReNeuroGen LLC——
2969The NanoMedicines Innovation Network——
2970Kartos Therapeutics——
2971CANCURE LLC——
2972ADMA BIOLOGICS, INC.——
2973Loop East Community Improvement District—$1.6M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 36
  • Methods of Treating Myelofibrosisapplication
  • Methods of Treating Myeloproliferative Neoplasmsapplication
  • Methods Of Treating Myeloproliferative Neoplasmsapplication
  • Methods Of Treating Cancer Dependent On Myc Gene Expresssionapplication
  • Methods Of Treating A Cancer Overexpressing One Or More BCL-2 Family Proteinsapplication
  • Methods of Treating Myeloproliferative Neoplasmsgranted
  • Methods of Treating Cancerapplication
  • Methods of Treating Cancergranted
  • Methods and Compositions of Treating an Ophthalmic Conditionapplication
  • Systems And Methods For Processing Clinical Trial Dataapplication
  • Systems And Methods For Processing Clinical Trial Dataapplication
  • Methods Of Treating Myeloproliferative Neoplasmsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.